Sentinel Lymph Node Biopsy in Breast Cancer: The Aarhus Experience

Authors

  • Mette Cathrine Lauridsen From the Departments of Surgery L, Denmark
  • Jens P. Garne From the Departments of Surgery L, Denmark
  • Ib Hessov From the Departments of Surgery L, Denmark
  • Flemming B. Sørensen Pathology, Denmark
  • Flemming Melsen Pathology, Denmark
  • Anders Lernevall Radiology, Aarhus University Hospital, Amtssygehuset, Aarhus, Denmark
  • Peer Christiansen From the Departments of Surgery L, Denmark

DOI:

https://doi.org/10.1080/028418600750013203

Abstract

Eighty patients, with newly diagnosed unifocal breast cancer and with no axillary metastases verified by ultrasonography, underwent sentinel lymph node (SLN) and subsequent axillary lymph node dissection. To identify the SLN, we used a combination of Tc-99m labelled colloid (Albures) and blue dye (Patent Blue V) injected peritumorally. Lymphoscintigraphy was not performed. The SLN was successfully identified in 78 out of 80 patients (97.5%); 43 patients (54%) were found to have metastatic disease. In 33 patients (77%) the SLN was the only node involved. No false-negative nodes were found, defined as SLNs that tested negative but with higher nodes that tested positive. If SLN biopsy is accepted as a routine procedure and when the exact indications are defined, the method described probably could be offered to the majority of breast cancer patients.

Downloads

Download data is not yet available.

Downloads

Published

2000-01-01

How to Cite

Cathrine Lauridsen, M., Garne, J. P., Hessov, I., Sørensen, F. B., Melsen, F., Lernevall, A., & Christiansen, P. (2000). Sentinel Lymph Node Biopsy in Breast Cancer: The Aarhus Experience. Acta Oncologica, 39(3), 421–422. https://doi.org/10.1080/028418600750013203

Issue

Vol. 39 No. 3 (2000): Acta Oncologica

Section

Articles